Immutep released more encouraging data from the TACTI-002 trial testing lead asset eftilagimod alpha ("efti") plus Merck & Co.'s anti-PD-1 pembrolizumab (Keytruda) in 1L & 2L non-small cell lung cancer ("NSCLC") and 2L head and neck squamous cell carcinoma ("HNSCC") ahead of a presentation today at 34th German Cancer Congress. The data demonstrates tumour responses at all levels of PDL-1 expression from >50% to <1%. At more than 7 months the trial has also yet to reach median progressionfree sur ....
19 Feb 2020
Efti-pembro combo: A new option in NSCLC?
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Efti-pembro combo: A new option in NSCLC?
Immutep released more encouraging data from the TACTI-002 trial testing lead asset eftilagimod alpha ("efti") plus Merck & Co.'s anti-PD-1 pembrolizumab (Keytruda) in 1L & 2L non-small cell lung cancer ("NSCLC") and 2L head and neck squamous cell carcinoma ("HNSCC") ahead of a presentation today at 34th German Cancer Congress. The data demonstrates tumour responses at all levels of PDL-1 expression from >50% to <1%. At more than 7 months the trial has also yet to reach median progressionfree sur ....